LEGN Valuation

Legend Biotech Corp

Add to Watchlist

Advanced Chart

35.950

+1.73(5.056%)1D

Overview
Forecast
Valuation
Earnings

LEGN Relative Valuation

LEGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LEGN is overvalued; if below, it's undervalued.

Historical Valuation

Legend Biotech Corp (LEGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.89 is considered Undervalued compared with the five-year average of -23.03. The fair price of Legend Biotech Corp (LEGN) is between 64.44 to 297.69 according to relative valuation methord. Compared to the current price of 34.22 USD , Legend Biotech Corp is Undervalued By 46.89%.

Relative Value

Fair Zone

64.44-297.69

Current Price：34.22

46.89%

Undervalued

146.87

Trailing

Forward

71.52

EV/EBITDA

Legend Biotech Corp. (LEGN) has a current EV/EBITDA of 71.52. The 5-year average EV/EBITDA is -22.17. The thresholds are as follows: Strongly Undervalued below -66.96, Undervalued between -66.96 and -44.56, Fairly Valued between 0.22 and -44.56, Overvalued between 0.22 and 22.62, and Strongly Overvalued above 22.62. The current Forward EV/EBITDA of 71.52 falls within the Strongly Overvalued range.

90.92

EV/EBIT

Legend Biotech Corp. (LEGN) has a current EV/EBIT of 90.92. The 5-year average EV/EBIT is -17.76. The thresholds are as follows: Strongly Undervalued below -64.64, Undervalued between -64.64 and -41.20, Fairly Valued between 5.68 and -41.20, Overvalued between 5.68 and 29.11, and Strongly Overvalued above 29.11. The current Forward EV/EBIT of 90.92 falls within the Strongly Overvalued range.

4.82

Legend Biotech Corp. (LEGN) has a current PS of 4.82. The 5-year average PS is 29.70. The thresholds are as follows: Strongly Undervalued below -11.99, Undervalued between -11.99 and 8.86, Fairly Valued between 50.55 and 8.86, Overvalued between 50.55 and 71.40, and Strongly Overvalued above 71.40. The current Forward PS of 4.82 falls within the Undervalued range.

83.83

P/OCF

Legend Biotech Corp. (LEGN) has a current P/OCF of 83.83. The 5-year average P/OCF is -33.95. The thresholds are as follows: Strongly Undervalued below -97.58, Undervalued between -97.58 and -65.76, Fairly Valued between -2.14 and -65.76, Overvalued between -2.14 and 29.68, and Strongly Overvalued above 29.68. The current Forward P/OCF of 83.83 falls within the Strongly Overvalued range.

894.30

P/FCF

Legend Biotech Corp. (LEGN) has a current P/FCF of 894.30. The 5-year average P/FCF is 8.61. The thresholds are as follows: Strongly Undervalued below -334.20, Undervalued between -334.20 and -162.80, Fairly Valued between 180.02 and -162.80, Overvalued between 180.02 and 351.42, and Strongly Overvalued above 351.42. The current Forward P/FCF of 894.30 falls within the Strongly Overvalued range.

Legend Biotech Corp (LEGN) has a current Price-to-Book (P/B) ratio of 6.10. Compared to its 3-year average P/B ratio of 7.99 , the current P/B ratio is approximately -23.65% higher. Relative to its 5-year average P/B ratio of 11.00, the current P/B ratio is about -44.54% higher. Legend Biotech Corp (LEGN) has a Forward Free Cash Flow (FCF) yield of approximately -4.53%. Compared to its 3-year average FCF yield of -2.97%, the current FCF yield is approximately 52.66% lower. Relative to its 5-year average FCF yield of -3.80% , the current FCF yield is about 19.30% lower.

6.10

P/B

Median3y

7.99

Median5y

11.00

-4.60

FCF Yield

Median3y

-2.97

Median5y

-3.80

Competitors Valuation Multiple

The average P/S ratio for LEGN's competitors is 9.82, providing a benchmark for relative valuation. Legend Biotech Corp Corp (LEGN) exhibits a P/S ratio of 4.82, which is -50.93% above the industry average. Given its robust revenue growth of 36.74%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Ionis Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Regencell Bioscience Holdings Ltd

Performance Decomposition

Market capitalization of LEGN decreased by 29.78% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -9.76 to -49.16.

The secondary factor is the Revenue Growth, contributed 36.74%to the performance.

Overall, the performance of LEGN in the past 1 year is driven by Margin Expansion. Which is more sustainable.

36.74%

186.52M → 255.06M

Revenue Growth

403.69%

-9.76 → -49.16

Margin Expansion

-470.21%

5.19 → -19.22

P/E Change

-29.78%